CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

NCT ID: NCT05631899

Last Updated: 2025-11-24

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-04-03
• Study Completion Date: 2026-12-30

Brief Summary

This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors to determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC vaccine loaded with KRAS mutant peptide (KRAS-EphA-2-CAR-DC) in combination with ICIs. It aims to: assess the safety and antitumor effects of KRAS-EphA-2-CAR-DC vaccine; detect T cell response against KRAS mutant peptide and tumor neoepitopes after the treatment with KRAS-EphA-2-CAR-DC vaccine and ICIs.

Detailed Description

Therapeutic cancer vaccines, especially DC-based vaccines, are extensively pursued immune approaches in addition to immune checkpoint blockade antibodies and chimeric antigen receptor T cells. DCs can engulf, process and present tumor antigens to T cells, thereby initiating a potent and tumor-specific immune response. However, clinical outcomes of therapeutic cancer vaccines still remain poor, with objective response rates that rarely exceed ~15%. The maturation and activation of DCs are necessary steps to trigger the antitumor responses. However, it is increasingly clear that tumor-infiltrating dendritic cells (TIDCs) usually have an immature or tolerated phenotype that plays central roles in developing tumor microenvironment (TME). As a consequence, malfunction of TIDCs could suppress the infiltration and function of tumor infiltrating T cells and convert them into immune suppressive regulatory T cells.

In our previous research, we constructed novel CAR-DCs (Chimeric antigen receptor engineered dendritic cells) containing a scFv domain targeting EphA2 antigen, CD8a transmembrane, tandem DC-specific activation domains. The engineered CAR-DCs were activated when contacting with tumor targets in TME, and consequently, augmented the cytotoxicity of antigen specific T cells in immune system humanized solid tumor mouse models. Our design of CAR-DCs provides an effective vaccine strategy for solid tumors. Therefore, we designed an autologous CAR-DC vaccine engineered with anti-EphA2 CAR and KRAS mutant peptide (KRAS-EphA-2-CAR-DC) , which can suppress the growth of tumors expressing the correlated KRAS mutant in animal models. In addition, the combination of the immune checkpoint inhibitors could further reverse immunosuppressive TME and globally activate T cell responses. In this pilot study, we aim to assess the safety, efficacy and immune response of KRAS-EphA-2-CAR-DC combined with anti-PD-1 antibody/anti-CTLA4 antibody in patients with local advanced/metastatic solid tumors.

Conditions

Solid Tumor, Adult; EphA2 Overexpression; KRAS G12V; KRAS G12C; KRAS G12D

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

KRAS-EphA-2-CAR-DC

In the priming phase, a conditioning chemotherapy regimen of Abraxane and cyclophosphamide is administered three days before vaccination, and KRAS-EphA-2-CAR-DC vaccine is infused on Day 0 and Day 7 in Week 1.

In the boost phase, KRAS-EphA-2-CAR-DC vaccine is infused one dose every 4 weeks since Week 5 for a total of 6 to 8 doses, then maintenance vaccination is given one dose every 8 weeks, until:

1. Unacceptable toxicity occurred or disease progression; or

2. Reactive T cells are undetected repeatedly after the last vaccine dose; or

3. Vaccine exhaustion.

Group Type: EXPERIMENTAL

KRAS-EphA-2-CAR-DC

Intervention Type: BIOLOGICAL

5\~10 × 10\^6 CAR-DCs per dose will be administered by intravenous injection.

Abraxane

Intervention Type: DRUG

Intravenous abraxane 125 mg/m\^2/day on day-5.

Cyclophosphamide

Intervention Type: DRUG

Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.

KRAS-EphA-2-CAR-DC plus anti-PD-1 antibody

In the priming phase, a conditioning chemotherapy regimen of Abraxane and cyclophosphamide is administered three days before vaccination, and KRAS-EphA-2-CAR-DC vaccine is infused on Day 0 and Day 7 in Week 1.

In the boost phase, KRAS-EphA-2-CAR-DC vaccine is infused one dose every 4 weeks since Week 5 for a total of 6 to 8 doses, then maintenance vaccination is given one dose every 8 weeks.

Anti-PD-1 antibody is administered 2 days after the first dose of KRAS-EphA-2-CAR-DC vaccine in the boost phase (Day 3 in Week 5) and every 4 weeks afterwards, until:

1. Unacceptable toxicity occurred or disease progression; or

2. Reactive T cells are undetected repeatedly after the last vaccine dose; or

3. Vaccine exhaustion.

Group Type: EXPERIMENTAL

KRAS-EphA-2-CAR-DC

Intervention Type: BIOLOGICAL

5\~10 × 10\^6 CAR-DCs per dose will be administered by intravenous injection.

Abraxane

Intervention Type: DRUG

Intravenous abraxane 125 mg/m\^2/day on day-5.

Cyclophosphamide

Intervention Type: DRUG

Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.

Anti-PD-1 antibody

Intervention Type: DRUG

Intravenous anti-PD-1 antibody 200 mg/day.

KRAS-EphA-2-CAR-DC plus anti-PD-1 antibody and anti-CTLA4 antibody

In the priming phase, a conditioning chemotherapy regimen of Abraxane and cyclophosphamide is administered three days before vaccination, and KRAS-EphA-2-CAR-DC vaccine is infused on Day 0 and Day 7 in Week 1.

In the boost phase, KRAS-EphA-2-CAR-DC vaccine is infused one dose every 8 weeks since Week 5.

Anti-PD-1 antibody and anti-CTLA4 antibody are administered 2 days after the first dose of KRAS-EphA-2-CAR-DC vaccine in the boost phase (Day 3 in Week 5) and every 3 weeks afterwards for four doses, followed by anti-PD-1 antibody once every 3 weeks, until:

1. Unacceptable toxicity occurred or disease progression; or

2. Reactive T cells are undetected repeatedly after the last vaccine dose; or

3. Vaccine exhaustion.

Group Type: EXPERIMENTAL

KRAS-EphA-2-CAR-DC

Intervention Type: BIOLOGICAL

5\~10 × 10\^6 CAR-DCs per dose will be administered by intravenous injection.

Abraxane

Intervention Type: DRUG

Intravenous abraxane 125 mg/m\^2/day on day-5.

Cyclophosphamide

Intervention Type: DRUG

Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.

Anti-PD-1 antibody

Intervention Type: DRUG

Intravenous anti-PD-1 antibody 200 mg/day.

Anti-CTLA4 Monoclonal Antibody

Intervention Type: DRUG

Intravenous anti-CTLA4 antibody 1 mg/kg/day

Interventions

KRAS-EphA-2-CAR-DC

5\~10 × 10\^6 CAR-DCs per dose will be administered by intravenous injection.

Intervention Type: BIOLOGICAL

Abraxane

Intravenous abraxane 125 mg/m\^2/day on day-5.

Intervention Type: DRUG

Cyclophosphamide

Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.

Intervention Type: DRUG

Anti-PD-1 antibody

Intravenous anti-PD-1 antibody 200 mg/day.

Intervention Type: DRUG

Anti-CTLA4 Monoclonal Antibody

Intravenous anti-CTLA4 antibody 1 mg/kg/day

Intervention Type: DRUG

Other Intervention Names

Abraxane Injectable Product; Cyclophosphamide for Injection; PD-1 blocking antibody; Ipilimumab

Eligibility Criteria

Inclusion Criteria

1. Age 18-75 (inclusive).

2. ECOG performance status ≤2 and Estimated life expectancy of more than 3 months.

3. Local advanced/metastatic solid tumors confirmed by histopathology or cytology with documentation of tumor EphA2 positive (≥20%) and KRAS mutation (G12V or G12D or G12C) within 6 months prior to screening. The second malignancy is allowed.

4. No clinical response to standard frontline therapy, or no standard therapy exists. Patients who have declined standard therapy or have no access to standard therapy may be enrolled and the reasons for lack of access need to be documented. Previous treatment with anti-PD-1/PD-L1 antibodies or anti-CTLA4 antibody are allowed, regardless of the level of PD-1/PD-L1 expression, dMMR and TMB.

5. At least one measurable lesion at baseline per RECIST version 1.1.

6. Adequate organ function as defined by the following criteria: ANC ≥1000 cells/μL; Platelet count ≥80,000/μL; Hemoglobin ≥8.0 g/dL; Serum AST and serum ALT, ≤3.0 x ULN (≤5 x ULN for patients with liver metastases); Total serum bilirubin ≤3.0 x ULN); Serum creatinine ≤2 x ULN or creatinine clearance of ≥45 mL/min.

7. Willing to undergo either excised or large-needle lymph node or tissue biopsy, or provide formalin-fixed paraffin-embedded (FFPE) tumor tissue block or freshly cut unstained slides.

8. Willing to complete all scheduled visits and assessments at the institution administering therapy.

9. Able to read, understand and provide written informed consent.

Exclusion Criteria

1. Having KRAS (G12V or G12D or G12C) germline mutation.

2. Active central nervous system disease involvement (but allow patients with prior brain metastases treated at least 4 weeks prior to enrollment that are clinically stable and do not require intervention), or prior history of NCI CTCAE Grade ≥3 drug-related CNS toxicity.

3. Prior organ allograft transplantations or allogeneic hematopoietic stem cell transplantation.

4. Evidence of active uncontrolled viral, bacterial, or systemic fungal infection.

5. Known positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS).

6. Active infection of hepatitis B virus (HBV), or hepatitis C virus (HCV).

7. Patients with history (within the last 5 years) or risk of autoimmune disease who have immunosuppressive medications or immunosuppressive doses of systemic corticosteroids (>10 mg/day prednisone or equivalent) within 28 days prior to enrollment. However, patients who received a short course of corticosteroids (eg, premedication prior to antibody drug) will be eligible for study entry.

8. Major trauma or major surgery within 4 weeks prior to enrollment.

9. Previous treatment involving KRAS mutant (G12V or G12D or G12C) and EphA2.

10. Systemic chemotherapy and other intervene within 2 weeks prior to vaccination.

11. Being participating or withdrew any other trials within 4 weeks.

12. Any serious underlying medical (eg, pulmonary, renal, hepatic, gastrointestinal, or neurological) or psychiatric condition or any issue that would limit compliance with study requirements.

13. Vaccination within 30 days of study enrollment.

14. Pregnant, lactating, or breastfeeding females.

15. Researchers believe that other reasons are not suitable for clinical trials.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zhejiang University

OTHER

Sponsor Role: collaborator

Chinese PLA General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Han weidong

Director of Biotherapeutic Department

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Yang Xu, Ph.D

Role: STUDY_DIRECTOR

Zhejiang University

Locations

Biotherapeutic Department of Chinsese PLA Gereral Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

CHN-PLAGH-BT-074

Identifier Type: -

Identifier Source: org_study_id